by Life Science Integrates | Sep 10, 2021 | Biotech, News, Pharma, Pharmatech
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.
by Life Science Integrates | Aug 3, 2021 | Biotech, News, Pharma, Pharmatech
Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS® technology can deliver to its drug development projects. The...
by Life Science Integrates | May 25, 2021 | Biotech, News, Pharma, Pharmatech
Together, Nanoform and Celanese will investigate the potential for enabling next-generation drug delivery devices by combining Nanoform’s nanoparticle platform technologies and Celanese’s VitalDose® EVA copolymer delivery technology.
by Life Science Integrates | May 18, 2021 | Biotech, News, Pharma, Pharmatech
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study.
by Life Science Integrates | Apr 21, 2021 | Biotech, News, Pharma, Pharmatech
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, announce that they are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms.
by Life Science Integrates | Mar 24, 2021 | Biotech, News, Pharma, Pharmatech
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has today launched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0.